ArticleFrontiers in oncology2026
Dose and normal tissue complication probability analysis of various radiotherapy regimens for thymomas.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to compare dosimetric differences and normal tissue complication probability (NTCP) among coplanar intensity-modulated radiation therapy (CO-IMRT), non-coplanar IMRT (NONCO-IMRT), coplanar volumetric-modulated arc therapy (CO-VMAT), and non-coplanar VMAT (NONCO-VMAT) in thymoma radiotherapy and clarify the value of non-coplanar plans. Methods: Forty-eight post-thymoma surgery patients were enrolled in this study. Four radiotherapy plans (50 Gy/25 fractions) were made for each patient. The target conformity index (CI), homogeneity index (HI), and organ-at-risk (OAR) (lungs, heart, etc.) dose parameters were then evaluated. NTCP was calculated using the Lyman-Kutcher-Burman (LKB) model. Statistical analysis was performed using the Student-Newman-Keuls (SNK-q) test (p < 0.05 for significance). Results: There were no significant clinical differences in target volume coverage and homogeneity among the four plans. The lung V Conclusion: All four plans meet the thymoma target dose requirement. However, NONCO-VMAT is preferred for its advantages in multi-organ protection and balanced breast dose. Additionally, CO-VMAT should be used cautiously in female patients due to the higher breast dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.